Literature DB >> 11106926

Over-expression of hepatocyte growth factor/scatter factor (HGF/SF) and the HGF/SF receptor (cMET) are associated with a high risk of metastasis and recurrence for children and young adults with papillary thyroid carcinoma.

R Ramirez1, D Hsu, A Patel, C Fenton, C Dinauer, R M Tuttle, G L Francis.   

Abstract

OBJECTIVE: The study determined if hepatocyte growth factor/scatter factor (HGF/SF) or the HGF/SF receptor (cMET) might be important for metastasis in thyroid cancer.
DESIGN: We examined HGF/SF and cMET expression by immunohistochemistry in a retrospective group of benign and malignant thyroid lesions from children and young adults, and correlated the intensity of expression with clinical outcome. PATIENTS: Patients included 42 children and young adults with papillary thyroid carcinomas (PTC), seven with follicular thyroid carcinomas (FTC), two with medullary thyroid carcinomas (MTC), 14 with benign thyroid disorders, and two with normal thyroids. MEASUREMENTS: Expression of cMET was graded from 0 (absent) to 4 (intense); and HGF/SF expression was graded from 0 (absent-minimal) to 3 (diffuse and intense).
RESULTS: cMET staining was greater in PTC (mean intensity 2.3 +/- 0.4 vs. 0.8 +/- 0.2, P < 0.005) and FTC (2.4 +/- 0.6 vs. 0.8 +/- 0.2, P = 0.04) than benign lesions (0.8 +/- 0.2) or normal thyroids (0.4 +/- 0.5). PTC with intense cMET staining had shorter disease free survival (P = 0.05) and increased HGF/SF staining (r = 0.39, P = 0.017). HGF/SF correlated with the extent of disease at diagnosis (r = 0.33, P = 0.049). Patients with PTC were stratified into quartiles based on combined cMET and HGF/SF staining. Those with intense cMET and HGF/SF staining were younger (P = 0.05), and had reduced disease free survival (P = 0.03).
CONCLUSIONS: We conclude that increased cMET and HGF/SF expression is associated with a high risk for metastasis and recurrence in children and young adults with papillary thyroid carcinoma.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11106926     DOI: 10.1046/j.1365-2265.2000.01124.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  24 in total

1.  c-Met inhibitor synergizes with tumor necrosis factor-related apoptosis-induced ligand to induce papillary thyroid carcinoma cell death.

Authors:  Rong Bu; Shahab Uddin; Maqbool Ahmed; Azhar R Hussain; Saif Alsobhi; Tarek Amin; Abdurahman Al-Nuaim; Fouad Al-Dayel; Jehad Abubaker; Prashant Bavi; Khawla S Al-Kuraya
Journal:  Mol Med       Date:  2012-03-27       Impact factor: 6.354

2.  c-MET as a potential therapeutic target and biomarker in cancer.

Authors:  J Rafael Sierra; Ming-Sound Tsao
Journal:  Ther Adv Med Oncol       Date:  2011-11       Impact factor: 8.168

Review 3.  Prognostic biomarkers in thyroid cancer.

Authors:  Paula Soares; Ricardo Celestino; Miguel Melo; Elsa Fonseca; Manuel Sobrinho-Simões
Journal:  Virchows Arch       Date:  2014-02-01       Impact factor: 4.064

4.  Immunoblot analysis of c-Met expression in human colorectal cancer: overexpression is associated with advanced stage cancer.

Authors:  Zhaoshi Zeng; Martin R Weiser; Matt D'Alessio; Andrew Grace; Jinru Shia; Philip B Paty
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

Review 5.  Current strategies for surgical management and adjuvant treatment of childhood papillary thyroid carcinoma.

Authors:  Geoffrey B Thompson; Ian D Hay
Journal:  World J Surg       Date:  2004-11-04       Impact factor: 3.352

6.  C. elegans as a model organism for in vivo screening in cancer: effects of human c-Met in lung cancer affect C. elegans vulva phenotypes.

Authors:  Shahid S Siddiqui; Sivakumar Loganathan; Soundararajan Krishnaswamy; Leonardo Faoro; Ramasamy Jagadeeswaran; Ravi Salgia
Journal:  Cancer Biol Ther       Date:  2008-03-05       Impact factor: 4.742

7.  In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.

Authors:  Frauke Bentzien; Marcus Zuzow; Nathan Heald; Anna Gibson; Yongchang Shi; Leanne Goon; Peiwen Yu; Stefan Engst; Wentao Zhang; Donghui Huang; Lora Zhao; Valentina Vysotskaia; Felix Chu; Rajana Bautista; Belinda Cancilla; Peter Lamb; Alison H Joly; F Michael Yakes
Journal:  Thyroid       Date:  2013-09-17       Impact factor: 6.568

8.  Targeting c-Met on gastric cancer cells through a fully human fab antibody isolated from a large naive phage antibody library.

Authors:  Bahareh Zarei; Zahra Javidan; Elnaz Fatemi; Fatemeh Rahimi Jamnani; Shohreh Khatami; Vahid Khalaj
Journal:  Daru       Date:  2020-03-19       Impact factor: 3.117

9.  Efficacy and mechanism of action of Deguelin in suppressing metastasis of 4T1 cells.

Authors:  Rajeshwari R Mehta; Harshadadevi Katta; Amit Kalra; Rutulkumar Patel; Akash Gupta; Fatouma Alimirah; Genoveva Murillo; Xinjian Peng; Aditya Unni; Miguel Muzzio; Rajendra G Mehta
Journal:  Clin Exp Metastasis       Date:  2013-05-05       Impact factor: 5.150

Review 10.  The pituitary tumor transforming gene in thyroid cancer.

Authors:  G D Lewy; N Sharma; R I Seed; V E Smith; K Boelaert; C J McCabe
Journal:  J Endocrinol Invest       Date:  2012-04-05       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.